Actively Recruiting
Phase 1 Study of JV-213 CAR T-cell Therapy for Adults with Relapsed or Refractory B-cell Lymphomas Evaluating Safety, Tolerability, and Dose Levels
Led by M.D. Anderson Cancer Center · Updated on 2026-07-29
33
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying JV-213, a new type of autologous CAR T-cell therapy targeting CD79b, in adults with relapsed or refractory B-cell lymphomas. The main goal is to find the highest dose of JV-213 that patients can tolerate safely. This Phase 1 trial also aims to evaluate the therapys safety, tolerability, and the best dose to use in future studies. Participants receive JV-213 through an intravenous infusion after their own immune cells are collected via leukapheresis. The study has two parts the first tests increasing doses of JV-213 in small groups to find the maximum tolerated dose, while the second part treats more patients at this recommended dose. Each participants treatment depends on the dose level assigned during the trial. Throughout the study, participants are closely monitored for side effects using standard criteria for adverse events. Researchers also assess tumor response and symptom relief to measure effectiveness. Blood and tumor samples are collected to study how the therapy works in the body and to identify biomarkers linked to treatment response or side effects. The study continues until December 2028, with approximately one year of follow-up after treatment to assess safety and outcomes.
CONDITIONS
Brief Title
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Research Team
S
Sattva Neelapu, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
